Benzinga · Mar 4, 2026
What's Going On With Anavex Life Sciences Stock On Wednesday?
Anavex Life Sciences' stock rises despite no news, up over 40% this year as investors watch Alzheimer's program updates and analyst targets.
NASDAQ · AVXL
Anavex Life Sciences Corp.
Healthcare · Biotechnology
$1.89
Down-$0.07 (-3.70%)
Updated Oct 3, 2026, 1:04 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 367.21M
- P/E ratio
- -7.28
- Dividend yield
- 0.00%
- 52-week range
- $1.88 – $10.38
- Volume
- 2.34M
- Avg. volume
- 2.3M
Price performance · AVXL
AVXL price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 1, 2026
AVXL closed at $1.89 after 19 trading sessions, down 33.92% for the selected period.
- Last close
- $1.89
- Period change
- -33.92%
- Period low
- $1.89
- Period high
- $2.86
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 1, 2026 | $2.00 | $2.01 | $1.88 | $1.89 | 2.34M |
| Sep 30, 2026 | $2.38 | $2.38 | $1.89 | $2.02 | 2.97M |
| Sep 29, 2026 | $2.35 | $2.415 | $2.31 | $2.36 | 1.76M |
| Sep 28, 2026 | $2.42 | $2.4308 | $2.35 | $2.35 | 522.54K |
| Sep 25, 2026 | $2.35 | $2.43 | $2.32 | $2.38 | 744.39K |
| Sep 24, 2026 | $2.33 | $2.37 | $2.27 | $2.34 | 937.05K |
| Sep 23, 2026 | $2.47 | $2.49 | $2.305 | $2.35 | 779.17K |
| Sep 22, 2026 | $2.41 | $2.485 | $2.39 | $2.47 | 639.99K |
| Sep 21, 2026 | $2.42 | $2.42 | $2.35 | $2.40 | 574.48K |
| Sep 18, 2026 | $2.42 | $2.45 | $2.38 | $2.42 | 920.59K |
| Sep 17, 2026 | $2.41 | $2.48 | $2.405 | $2.41 | 364.75K |
| Sep 16, 2026 | $2.44 | $2.4699 | $2.31 | $2.36 | 906.1K |
| Sep 15, 2026 | $2.59 | $2.59 | $2.43 | $2.44 | 946.24K |
| Sep 14, 2026 | $2.61 | $2.64 | $2.55 | $2.60 | 658.13K |
| Sep 11, 2026 | $2.71 | $2.7373 | $2.61 | $2.62 | 624.49K |
| Sep 10, 2026 | $2.71 | $2.735 | $2.615 | $2.66 | 433.77K |
| Sep 9, 2026 | $2.84 | $2.895 | $2.74 | $2.75 | 438.58K |
| Sep 8, 2026 | $2.81 | $2.88 | $2.77 | $2.85 | 559.14K |
| Sep 4, 2026 | $2.82 | $2.905 | $2.81 | $2.86 | 307.15K |
Latest AVXL news
The latest Smart Investors Daily articles mentioning AVXL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AVXL research
Overview
Company profile and research snapshot.
Company profile
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $11.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 31, 2026 | D. Boral Capital | Buy | — |
| Mar 26, 2026 | D. Boral Capital | Buy | — |
| Mar 23, 2026 | D. Boral Capital | Buy | — |
| Feb 10, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 9, 2026 | D. Boral Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 10, 2026
HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $20 price target.
SeekingAlpha · Feb 10, 2026
Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory
Anavex Life Sciences faces regulatory setbacks after the EMA adopted a negative opinion of blarcamesine in Alzheimer's. Find out why AVXL stock is a Sell.
Benzinga · Feb 9, 2026
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $24 Price Target
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $24 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
